About gni ltd - GNIIF
GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. It operates through the following geographical segments: Japan and China. The Japan segment deals with licensing, preclinical studies, clinical trials, and sales. The China segment covers the integrated bio-pharma operations consisting of validation, preclinical trials, formulation, phase I to III clinical trials, manufacturing and sales. The company was founded on November 20, 2001 and is headquartered in Tokyo, Japan.
GNIIF At a Glance
GNI Group Ltd.
Nihonbashi-Honcho YS Building, 3/F
Tokyo, Tokyo 103-0023
| Phone | 81-3-6214-3600 | Revenue | 184.98M | |
| Industry | Biotechnology | Net Income | 57.56M | |
| Sector | Health Technology | 2023 Sales Growth | 39.675% | |
| Fiscal Year-end | 12 / 2024 | Employees | 843 | |
| View SEC Filings |
GNIIF Valuation
| P/E Current | 17.786 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 16.652 |
| Price to Sales Ratio | 5.306 |
| Price to Book Ratio | 4.174 |
| Price to Cash Flow Ratio | 21.071 |
| Enterprise Value to EBITDA | 26.20 |
| Enterprise Value to Sales | 5.227 |
| Total Debt to Enterprise Value | 0.138 |
GNIIF Efficiency
| Revenue/Employee | 219,430.549 |
| Income Per Employee | 68,284.368 |
| Receivables Turnover | 6.466 |
| Total Asset Turnover | 0.529 |
GNIIF Liquidity
| Current Ratio | 3.772 |
| Quick Ratio | 3.488 |
| Cash Ratio | 2.825 |
GNIIF Profitability
| Gross Margin | 86.239 |
| Operating Margin | 17.61 |
| Pretax Margin | 48.556 |
| Net Margin | 31.119 |
| Return on Assets | 16.457 |
| Return on Equity | 28.88 |
| Return on Total Capital | 15.419 |
| Return on Invested Capital | 19.408 |
GNIIF Capital Structure
| Total Debt to Total Equity | 55.745 |
| Total Debt to Total Capital | 35.792 |
| Total Debt to Total Assets | 30.193 |
| Long-Term Debt to Equity | 49.977 |
| Long-Term Debt to Total Capital | 32.089 |